Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection

Akinlolu O. Ojo, Herwig Ulf Meier-Kriesche, Julie A. Hanson, Alan B. Leichtman, Diane Cibrik, John C. Magee, Robert A. Wolfe, Lawrence Y. Agodoa, Bruce Kaplan

Research output: Contribution to journalArticle

388 Citations (Scopus)

Abstract

Background. Mycophenolate Mofetil (MMF) has been shown to significantly decrease the number of acute rejection episodes in renal transplant recipients during the 1st year. A beneficial effect of MMF on long-term graft survival has been more difficult to demonstrate. This beneficial effect has not been detected, despite the impact of acute rejection on the development of chronic allograft nephropathy and experimental evidence that MMF may have a salutary effect on chronic allograft nephropathy independent of that of rejection. Methods. Data on 66,774 renal transplant recipients from the U.S. renal transplant scientific registry were analyzed. Patients who received a solitary renal transplant between October 1, 1988 and June 30, 1997 were studied. The Cox proportional hazard regression was used to estimate relevant risk factors. Kaplan-Meier analysis was performed for censored graft survival. Results. MMF decreased the relative risk for development of chronic allograft failure (CAF) by 27% (risk ratio [RR] 0.73, P

Original languageEnglish (US)
Pages (from-to)2405-2409
Number of pages5
JournalTransplantation
Volume69
Issue number11
StatePublished - Jun 15 2000
Externally publishedYes

Fingerprint

Mycophenolic Acid
Allografts
Kidney
Graft Survival
Transplants
Kaplan-Meier Estimate
Registries
Odds Ratio
Transplant Recipients

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Ojo, A. O., Meier-Kriesche, H. U., Hanson, J. A., Leichtman, A. B., Cibrik, D., Magee, J. C., ... Kaplan, B. (2000). Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation, 69(11), 2405-2409.

Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. / Ojo, Akinlolu O.; Meier-Kriesche, Herwig Ulf; Hanson, Julie A.; Leichtman, Alan B.; Cibrik, Diane; Magee, John C.; Wolfe, Robert A.; Agodoa, Lawrence Y.; Kaplan, Bruce.

In: Transplantation, Vol. 69, No. 11, 15.06.2000, p. 2405-2409.

Research output: Contribution to journalArticle

Ojo, AO, Meier-Kriesche, HU, Hanson, JA, Leichtman, AB, Cibrik, D, Magee, JC, Wolfe, RA, Agodoa, LY & Kaplan, B 2000, 'Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection', Transplantation, vol. 69, no. 11, pp. 2405-2409.
Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000 Jun 15;69(11):2405-2409.
Ojo, Akinlolu O. ; Meier-Kriesche, Herwig Ulf ; Hanson, Julie A. ; Leichtman, Alan B. ; Cibrik, Diane ; Magee, John C. ; Wolfe, Robert A. ; Agodoa, Lawrence Y. ; Kaplan, Bruce. / Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. In: Transplantation. 2000 ; Vol. 69, No. 11. pp. 2405-2409.
@article{bb95aebd2872465fb0217a7d3dddc3f8,
title = "Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection",
abstract = "Background. Mycophenolate Mofetil (MMF) has been shown to significantly decrease the number of acute rejection episodes in renal transplant recipients during the 1st year. A beneficial effect of MMF on long-term graft survival has been more difficult to demonstrate. This beneficial effect has not been detected, despite the impact of acute rejection on the development of chronic allograft nephropathy and experimental evidence that MMF may have a salutary effect on chronic allograft nephropathy independent of that of rejection. Methods. Data on 66,774 renal transplant recipients from the U.S. renal transplant scientific registry were analyzed. Patients who received a solitary renal transplant between October 1, 1988 and June 30, 1997 were studied. The Cox proportional hazard regression was used to estimate relevant risk factors. Kaplan-Meier analysis was performed for censored graft survival. Results. MMF decreased the relative risk for development of chronic allograft failure (CAF) by 27{\%} (risk ratio [RR] 0.73, P",
author = "Ojo, {Akinlolu O.} and Meier-Kriesche, {Herwig Ulf} and Hanson, {Julie A.} and Leichtman, {Alan B.} and Diane Cibrik and Magee, {John C.} and Wolfe, {Robert A.} and Agodoa, {Lawrence Y.} and Bruce Kaplan",
year = "2000",
month = "6",
day = "15",
language = "English (US)",
volume = "69",
pages = "2405--2409",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection

AU - Ojo, Akinlolu O.

AU - Meier-Kriesche, Herwig Ulf

AU - Hanson, Julie A.

AU - Leichtman, Alan B.

AU - Cibrik, Diane

AU - Magee, John C.

AU - Wolfe, Robert A.

AU - Agodoa, Lawrence Y.

AU - Kaplan, Bruce

PY - 2000/6/15

Y1 - 2000/6/15

N2 - Background. Mycophenolate Mofetil (MMF) has been shown to significantly decrease the number of acute rejection episodes in renal transplant recipients during the 1st year. A beneficial effect of MMF on long-term graft survival has been more difficult to demonstrate. This beneficial effect has not been detected, despite the impact of acute rejection on the development of chronic allograft nephropathy and experimental evidence that MMF may have a salutary effect on chronic allograft nephropathy independent of that of rejection. Methods. Data on 66,774 renal transplant recipients from the U.S. renal transplant scientific registry were analyzed. Patients who received a solitary renal transplant between October 1, 1988 and June 30, 1997 were studied. The Cox proportional hazard regression was used to estimate relevant risk factors. Kaplan-Meier analysis was performed for censored graft survival. Results. MMF decreased the relative risk for development of chronic allograft failure (CAF) by 27% (risk ratio [RR] 0.73, P

AB - Background. Mycophenolate Mofetil (MMF) has been shown to significantly decrease the number of acute rejection episodes in renal transplant recipients during the 1st year. A beneficial effect of MMF on long-term graft survival has been more difficult to demonstrate. This beneficial effect has not been detected, despite the impact of acute rejection on the development of chronic allograft nephropathy and experimental evidence that MMF may have a salutary effect on chronic allograft nephropathy independent of that of rejection. Methods. Data on 66,774 renal transplant recipients from the U.S. renal transplant scientific registry were analyzed. Patients who received a solitary renal transplant between October 1, 1988 and June 30, 1997 were studied. The Cox proportional hazard regression was used to estimate relevant risk factors. Kaplan-Meier analysis was performed for censored graft survival. Results. MMF decreased the relative risk for development of chronic allograft failure (CAF) by 27% (risk ratio [RR] 0.73, P

UR - http://www.scopus.com/inward/record.url?scp=0034660104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034660104&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 2405

EP - 2409

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -